Language Select
Varian Logo

Press Releases

April 24, 2019
Second Quarter 2019 Summary – Oncology gross orders grew 15% in dollars, or 18% in constant currency – Total company revenues grew 7% in dollars, or 10% in constant currency, to $779 million... Read more
April 23, 2019
Varian (NYSE: VAR) today announced that The Nairobi West Hospital in Nairobi, Kenya is the first clinic in the country and in West, Central, and East Africa to begin treating cancer patients using... Read more
April 23, 2019
Varian (NYSE: VAR) today announced it will be showcasing its new single-room proton therapy system, ProBeam® 360°, and the Bravos™ afterloader system for High Dose Rate (HDR) brachytherapy... Read more
April 08, 2019
Varian (NYSE: VAR) today announced the installation of the cyclotron for the Varian ProBeam® proton therapy system at Hefei Ion Medical Center (HIMC) in China. The cyclotron is a core piece of... Read more
April 03, 2019
At a grand opening ceremony held March 8th, the Varian office in Hertford Office Park, Midrand, Johannesburg, South Africa was officially inaugurated. Prior to the opening of the permanent... Read more
April 03, 2019
At the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, GA, Varian (NYSE: VAR), in partnership with the University of Maryland School of Medicine's Department of... Read more
April 02, 2019
Varian (NYSE: VAR) today announced a 62-year-old male with thyroid cancer was the first patient in Malaysia to be treated on the Halcyon™ system at Beacon Hospital in Selangor. Halcyon... Read more
März 26, 2019
Varian (NYSE: VAR) today announced a 55-year-old male with liver cancer at the Korea University Medical Center Anam Hospital, was the first patient in Korea to receive treatment on the Halcyon™... Read more
März 25, 2019
Varian (NYSE: VAR) today announced it again received the "Best After-Sales Service Award for Radiotherapy Products" in the 2018 Chinese Medical Devices Industry Data and After-Sales Service... Read more
März 21, 2019
Building on its market-leading efforts in preclinical research aimed at clinical implementation of Flash therapy, Varian (NYSE: VAR) hosted the first meeting of the FlashForward™ Consortium in... Read more

Corporate Communications Contact

Mark Plungy
Director, Public Relations
650.424.5630
mark.plungy@varian.com

Investor Relations Contact

Mike Bruff
SVP, Investor Relations
650.424.5163
investors@varian.com